We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NTRA's EXPAND trial for Fetal Focus single-gene NIPT passed 2,000 patients, more than doubling over 12 months.
EXPAND data were presented at the February 2026 SMFM meeting, with genetic confirmation of outcomes.
Natera says LinkedSNP can detect inherited variants, identifying all five complex homozygous cases so far.
Natera (NTRA - Free Report) recently announced that its EXPAND clinical trial evaluating the Fetal Focus single-gene noninvasive prenatal test (NIPT) has exceeded 2,000 patients, representing more than a twofold increase over the past year.
The milestone comes shortly after positive EXPAND data were presented during an oral plenary session at the Society for Maternal-Fetal Medicine Annual Meeting in February 2026. The data showcased clinical performance in the first milestone readout of EXPAND and emphasized the trial’s robust design, including genetic confirmation of all outcomes.
Per management, the company developed Fetal Focus to expand the scope of noninvasive prenatal testing. Enrollment of more than 2,000 patients strengthens EXPAND’s role in establishing a new standard for clinical evidence in single-gene NIPT while supporting clinicians and families with high-quality data.
Likely Trend of NTRA Stock Following the News
Following the announcement, the company's shares gained 4.5% at yesterday’s closing. In the year-to-date period, shares of the company have fallen 10.6% compared with the industry’s 11.2% decline. However, the S&P 500 has risen 8.1% in the same timeframe.
The enrollment milestone and clinical validation of Fetal Focus may strengthen investor confidence in Natera’s women’s health portfolio. Positive clinical data and expanding physician awareness could support broader adoption of single-gene NIPT solutions, potentially enhancing the company’s competitive position in the prenatal diagnostics market.
NTRA currently has a market capitalization of $28.08 billion.
Image Source: Zacks Investment Research
More on the News
EXPAND is a prospective, blinded, multi-site clinical trial designed to evaluate the clinical performance of Natera’s Fetal Focus single-gene noninvasive prenatal test (NIPT). Fetal Focus provides fetal risk assessment for 21 genes associated with severe early-onset genetic conditions. The test is intended for pregnant patients who receive a positive result on Natera’s Horizon carrier screening test when paternal carrier testing is unavailable.
Natera’s proprietary ultra-sensitive LinkedSNP technology determines whether disease-causing variants have been inherited from one or both parents. The technology has demonstrated strong performance in complex homozygous cases, successfully identifying all five such cases evaluated to date.
Industry Prospects Favoring the Market
Going by the data provided by Coherent Market Insights, the non-invasive prenatal testing market is valued at $5.62 billion in 2026 and is expected to witness a CAGR of 10.6% through 2033.
Factors like the increasing prevalence of chromosomal abnormalities among newborns and growing awareness and acceptance of non-invasive prenatal testing methods are driving the market’s growth.
Other News
Natera recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
Key Takeaways
Natera (NTRA - Free Report) recently announced that its EXPAND clinical trial evaluating the Fetal Focus single-gene noninvasive prenatal test (NIPT) has exceeded 2,000 patients, representing more than a twofold increase over the past year.
The milestone comes shortly after positive EXPAND data were presented during an oral plenary session at the Society for Maternal-Fetal Medicine Annual Meeting in February 2026. The data showcased clinical performance in the first milestone readout of EXPAND and emphasized the trial’s robust design, including genetic confirmation of all outcomes.
Per management, the company developed Fetal Focus to expand the scope of noninvasive prenatal testing. Enrollment of more than 2,000 patients strengthens EXPAND’s role in establishing a new standard for clinical evidence in single-gene NIPT while supporting clinicians and families with high-quality data.
Likely Trend of NTRA Stock Following the News
Following the announcement, the company's shares gained 4.5% at yesterday’s closing. In the year-to-date period, shares of the company have fallen 10.6% compared with the industry’s 11.2% decline. However, the S&P 500 has risen 8.1% in the same timeframe.
The enrollment milestone and clinical validation of Fetal Focus may strengthen investor confidence in Natera’s women’s health portfolio. Positive clinical data and expanding physician awareness could support broader adoption of single-gene NIPT solutions, potentially enhancing the company’s competitive position in the prenatal diagnostics market.
NTRA currently has a market capitalization of $28.08 billion.
Image Source: Zacks Investment Research
More on the News
EXPAND is a prospective, blinded, multi-site clinical trial designed to evaluate the clinical performance of Natera’s Fetal Focus single-gene noninvasive prenatal test (NIPT). Fetal Focus provides fetal risk assessment for 21 genes associated with severe early-onset genetic conditions. The test is intended for pregnant patients who receive a positive result on Natera’s Horizon carrier screening test when paternal carrier testing is unavailable.
Natera’s proprietary ultra-sensitive LinkedSNP technology determines whether disease-causing variants have been inherited from one or both parents. The technology has demonstrated strong performance in complex homozygous cases, successfully identifying all five such cases evaluated to date.
Industry Prospects Favoring the Market
Going by the data provided by Coherent Market Insights, the non-invasive prenatal testing market is valued at $5.62 billion in 2026 and is expected to witness a CAGR of 10.6% through 2033.
Factors like the increasing prevalence of chromosomal abnormalities among newborns and growing awareness and acceptance of non-invasive prenatal testing methods are driving the market’s growth.
Other News
Natera recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.
Natera, Inc. Price
Natera, Inc. price | Natera, Inc. Quote
NTRA’s Zacks Rank & Key Picks
Natera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.